Healthcare / Drug Manufacturers - Specialty & GenericBSE
$814.35
+15.25 (+1.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $372.7M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16.8B
P/E
26.2x
↑EV/EBITDA
14.5x
↑ROE
11.4%
↑Gross Margin
38.4%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+21.0%
FCF CAGR
—
FCF margin
4.1%
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.04B · net income $664.6M · FCF $372.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.04B | $9.04B | $7.60B | $6.29B | $5.11B |
| Net Income | $664.6M | $664.6M | $609.9M | $581.9M | $426.3M |
| EBITDA | $1.23B | $1.23B | $1.12B | $916.4M | $701.9M |
| EPS | 31.15 | 31.15 | 28.80 | 27.88 | 19.70 |
| Gross Margin | 38.4% | 38.4% | 37.9% | 37.0% | 36.3% |
| Operating Margin | 8.2% | 8.2% | 8.7% | 10.3% | 9.4% |
| Net Margin | 7.4% | 7.4% | 8.0% | 9.3% | 8.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 |
| Current Ratio | 1.95 | 1.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $372.7M | $372.7M | $159.9M | $712.8M | $-99.3M |
| Returns | |||||
| ROE | 11.4% | 11.4% | 12.1% | 12.9% | 10.6% |
| Valuation | |||||
| P/E | 26.17 | 26.17 | 34.18 | 19.86 | 12.50 |
| EV/EBITDA | 14.46 | 14.46 | 18.88 | 12.59 | 7.61 |
| P/B | 2.99 | 2.99 | 4.12 | 2.57 | 1.32 |
| Growth & Yield | |||||
| Revenue Growth | 19.0% | 19.0% | 20.8% | 23.2% | — |
| EPS Growth | 8.2% | 8.2% | 3.3% | 41.5% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
32.4%
EPS terminal req.
$72.26
Spread vs growth
-24.2%
5Y implied EPS CAGR
22.9%
EPS terminal req.
$87.43
Spread vs growth
-14.8%
10Y implied EPS CAGR
16.3%
EPS terminal req.
$140.81
Spread vs growth
-8.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.5%
Start / end P/E
33.7x → 26.7x
EPS bridge
28.80 → 31.15
Residual
-1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.